{
    "clinical_study": {
        "@rank": "95666", 
        "arm_group": [
            {
                "arm_group_label": "Placebo 0 mg/d", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers"
            }, 
            {
                "arm_group_label": "Dihydrocapsiate 9 mg/d", 
                "arm_group_type": "Active Comparator", 
                "description": "9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to test the effect of dihydrocapsiate on energy expenditure\n      in women."
        }, 
        "brief_title": "Effect of Dihydrocapsiate on Energy Expenditure in Women", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "Capsaicin, a substance found in chili pepper, is known to stimulate thermogenesis.\n      Dihydrocapsiate, a capsinoid, found in the non-pungent CH-19 sweet pepper has similar\n      thermogenic effects without the gastrointestinal side effects. The objective of this project\n      is to test the effect of 12 weeks of daily consumption of 9 mg dihydrocapsiate on resting\n      energy expenditure relative to baseline when compared to a control group consuming products\n      without DCT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI: 18.5-34.5 kg/m2\n\n          -  Good general health\n\n          -  Low to mild physical activity\n\n          -  Willing to maintain habitual diet and physical activity patterns throughout the study\n             period\n\n          -  Premenopausal and cycling regularly or using oral contraceptives\n\n          -  Willing to attend study visits only during the follicular phase or bleed phase of\n             their menstrual cycle\n\n          -  Understands study procedures and signs forms providing informed consent to\n             participate in the study\n\n          -  Have spoken and written English literacy\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus or any conditions that might affect energy metabolism\n\n          -  Weight change \u00b12 kg over previous three months\n\n          -  Known sensitivity or allergy to ingredients of the study products\n\n          -  Non-breakfast eater\n\n          -  Recent use of antibiotics\n\n          -  History of smoking during the six months prior to study\n\n          -  Recent signs or symptoms of infection, including cold or flu-like symptoms\n\n          -  Concurrent or recent intervention study participation\n\n          -  Instability in breathing patterns or energy expenditure measures\n\n          -  History of drug or alcohol abuse\n\n          -  Lipid-lowering, anti-hypertensive or anti-inflammatory steroid medication use\n\n          -  Weight loss medication\n\n          -  Pregnant or lactating\n\n          -  Unwilling to be randomized to any experimental group and unable to meet all\n             requirements of the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773356", 
            "org_study_id": "WASABI"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo 0 mg/d", 
                "Dihydrocapsiate 9 mg/d"
            ], 
            "description": "Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo.  Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.", 
            "intervention_name": "Dihydrocapsiate", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Natural substances present in sweet chili peppers"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Obesity", 
            "Body Weight", 
            "Body Composition", 
            "Metabolism", 
            "Resting Energy Expenditure"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30602-6554"
                }, 
                "name": "University of Georgia, Department of Kinesiology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Controlled, Parallel Trial to Evaluate the Effects of Dihydrocapsiate on Energy Expenditure in Women", 
        "overall_official": {
            "affiliation": "University of Georgia", 
            "last_name": "Ellen M Evans, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Resting Energy Expenditure", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline at 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773356"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Georgia", 
            "investigator_full_name": "Ellen Evans", 
            "investigator_title": "Dr Ellen Evans", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Thermic effect of feeding", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 12 weeks"
            }, 
            {
                "measure": "Body Composition", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 12 weeks"
            }
        ], 
        "source": "University of Georgia", 
        "sponsors": {
            "collaborator": {
                "agency": "Kellogg Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ellen Evans", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}